Corvus Pharmaceuticals
Small molecule cancer therapeutics with novel mechanisms of action
- Sector
- Biotech
- Headquarters
- BURLINGAME, CA
- Founded
- 2014
- Latest Form D
- $75M, Sep 2015
- Total capital
- $87.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $87.7M
- 2 Form D · last Sep 2015
- 133 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 14
- 26 pending · first 2020
- Rank in peer group#122 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$75M
- Private capital raisedForm D · SEC · 1st filing$12.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#122 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Elisha (Terry) P. GouldDirectorNamed in SEC Form D filings
- Leiv G. LeaExecutive OfficerNamed in SEC Form D filings
- Peter P. MoldtDirectorNamed in SEC Form D filings
- Peter P. ThompsonDirectorNamed in SEC Form D filings
- Richard A. MillerExecutive Officer, DirectorNamed in SEC Form D filings
- Terry G. GouldDirectorNamed in SEC Form D filings
What it has protected
USPTO · 14 granted of 40- PendingCompounds And Methods For Modulating INTERLEUKIN-2-INDUCIBLE T-cell KinaseUSPTOApplication 19569194
- GrantedCompounds And Methods For Modulating INTERLEUKIN-2-INDUCIBLE T-cell KinaseUSPTOUS 12,686,677
- GrantedANTI-CD73 AntibodiesUSPTOUS 12,351,644
Show all 40 patent records
- Compounds And Methods For Modulating INTERLEUKIN-2-INDUCIBLE T-cell KinaseJul 23, 2026 · Application 19569194Pending
- Compounds And Methods For Modulating INTERLEUKIN-2-INDUCIBLE T-cell KinaseJul 21, 2026 · US 12,686,677Granted
- ANTI-CD73 AntibodiesJul 8, 2025 · US 12,351,644Granted
- Itk Inhibitors For Increasing TH1 Cell ActivityJul 3, 2025 · Application 18852735Pending
- Methods For Detecting And Treating Cancers Having Adenosine Pathway ActivationDec 24, 2024 · US 12,174,192Granted
- Compounds And Methods For Modulating INTERLEUKIN-2-INDUCIBLE T-cell KinaseNov 21, 2024 · Application 18439695Pending
- Methods For Detecting And Treating Cancers Having Adenosine Pathway ActivationOct 15, 2024 · US 12,116,635Granted
- ANTI-CD73 Compounds To Treat Oncovirus-positive CancersSep 12, 2024 · Application 18289261Pending
- Immunomodulatory ANTI-CD73 Antibodies And Uses ThereofJul 4, 2024 · Application 17772092Pending
- Methods Of Treating CancerJul 2, 2024 · US 12,023,337Granted
- Compounds And Methods For Modulating INTERLEUKIN-2-INDUCIBLE T-cell KinaseFeb 13, 2024 · US 11,897,874Granted
- B-cell Activating CD73 AntibodiesAug 4, 2022 · Application 17290961Pending
- Pharmaceutical FormulationsMar 8, 2022 · US 11,266,649Granted
- Compounds And Methods For Modulating Adenosine A2B Receptor And Adenosine A2A ReceptorFeb 22, 2022 · US 11,254,686Granted
- Methods Of Treating CancerJun 22, 2021 · US 11,040,040Granted
- Compounds And Methods For Modulating INTERLEUKIN-2-INDUCIBLE T-cell KinaseMay 18, 2021 · US 11,008,314Granted
- Methods For Treating CD73HI TumorsApr 15, 2021 · Application 16500654Pending
- Methods Of Treating CancerFeb 9, 2021 · US 10,912,776Granted
- Adenosine Pathway Inhibitors For Cancer TreatmentJan 14, 2021 · Application 16761749Pending
- Compounds And Methods For Modulating Bruton's Tyrosine KinaseDec 22, 2020 · US 10,870,652Granted
- ANTI-CD73 AntibodiesOct 6, 2020 · US 10,793,636Granted
- Combination Therapy For Cancer TreatmentAug 20, 2020 · Application 16761751Pending
- Processes For Making TRIAZOLO[4,5D] Pyramidine Derivatives And Intermediates ThereofMay 19, 2020 · US 10,654,825Granted
- Compounds And Methods For Modulating Adenosine A2B Receptor And Adenosine A2A ReceptorMar 12, 2020 · Application 16557694Pending
- Pharmaceutical FormulationsAug 1, 2019 · Application 16265078Pending
- Methods Of Treating CancerJan 24, 2019 · Application 15945677Pending
- Methods For Detecting And Treating Cancers Having Adenosine Pathway ActivationApplication 62846525Pending
- Methods For Detecting And Treating Cancers Having Adenosine Pathway ActivationApplication 62846524Pending
- Pharmaceutical FormulationsApplication PCTUS2019016284Pending
- Methods For Detecting Adenosine Pathway ActivationApplication 62757623Pending
- Combined Adenosine Receptor Inhibitor-atezolizumab Treatment For CancerApplication 62757630Pending
- Combination Therapy For Cancer TreatmentApplication PCTUS2018059481Pending
- Adenosine Pathway Inhibitors For Cancer TreatmentApplication PCTUS2018059480Pending
- B-Cell Activating CD73 AntibodyApplication 62756065Pending
- Methods For Detecting Adenosine Pathway ActivationApplication 62742912Pending
- Combined Adenosine Receptor Inhibitor-atezolizumab Treatment For CancerApplication 62742919Pending
- Processes For Making TRIAZOLO[4,5D] Pyramidine Derivatives And Intermediates ThereofApplication 62737839Pending
- Compounds And Methods For Modulating Adenolsine A28 Receptor And Adenosine A2A ReceptorApplication PCTUS2018049206Pending
- Compounds And Methods For Modulating Adenosine A2B Receptor And Adenosine A2A ReceptorApplication 62725621Pending
- Methods For Treating CD73HI TumorsApplication PCTUS2018026142Pending
Related companies, and why
- NAVIGEN, INC.Similar federal contract value in Biotech · null in contracts
- Cabaletta BioSimilar federal contract value in Biotech · null in contracts
- Trotana TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Charm TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Knopp Biosciences LLCSimilar federal contract value in Biotech · null in contracts
- Proxima Bio, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .